公开(公告)号：US20180127406A1

公开(公告)日：2018-05-10

申请号：US15623866

申请日：2017-06-15

Applicant: Oryzon Genomics S.A.

Inventor： Alberto ORTEGA MUÑOZ ,  Matthew Colin Thor FYEE ,  Marc MARTINELL PEDEMONTE ,  Iñigo TIRAPU FERNANDEZ DE LA CUESTA ,  Maria de los Ángeles ESTIARTE MARTINEZ

IPC: C07D417/12 ,  A61K31/422 ,  C07D213/73 ,  A61K31/433 ,  C07D285/08 ,  C07D285/135 ,  C07D413/12 ,  C07D401/12 ,  C07D285/12 ,  C07D277/40 ,  C07D271/113 ,  C07D271/07 ,  C07D263/48 ,  C07D261/14 ,  C07D253/07 ,  C07D241/20 ,  C07D239/42 ,  C07D237/20 ,  A61K31/4245

CPC classification number: C07D417/12 ,  A61K31/422 ,  A61K31/4245 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/506 ,  C07D213/73 ,  C07D237/20 ,  C07D239/42 ,  C07D241/20 ,  C07D253/07 ,  C07D261/14 ,  C07D263/48 ,  C07D271/07 ,  C07D271/113 ,  C07D277/40 ,  C07D285/08 ,  C07D285/12 ,  C07D285/135 ,  C07D401/12 ,  C07D413/12

Abstract: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. Thus, in one specific aspect the invention relates to formulas (II), (III), (IV), (V), (VI), (VII), (VIII), (IX).